Stock 300199 HYBIO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hybio Pharmaceutical Co., Ltd.

Equities

300199

CNE1000011T7

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 22/05/2024 BST 		5-day change 1st Jan Change
11.91 CNY -4.34% Intraday chart for Hybio Pharmaceutical Co., Ltd. +1.02% -12.30%
05-21 Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee MT
04-26 Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 8,670 5,161 5,917 11,138 15,527 11,994
Enterprise Value (EV) 1 8,877 6,371 7,414 12,310 17,067 13,660
P/E ratio -25.2 x -6.04 x -10.1 x 420 x -41.9 x -23.4 x
Yield - - - - - -
Capitalization / Revenue 6.86 x 8.4 x 8.2 x 15.1 x 22 x 27.8 x
EV / Revenue 7.02 x 10.4 x 10.3 x 16.7 x 24.2 x 31.7 x
EV / EBITDA 32.5 x -16.1 x -16.8 x -109 x -292 x -103 x
EV / FCF -21 x -14.3 x -66.3 x -72.7 x -96.1 x 146 x
FCF Yield -4.77% -7.01% -1.51% -1.38% -1.04% 0.68%
Price to Book 2.55 x 2.65 x 3.59 x 7.03 x 12.2 x 15 x
Nbr of stocks (in thousands) 928,267 889,843 889,843 883,241 883,241 883,241
Reference price 2 9.340 5.800 6.650 12.61 17.58 13.58
Announcement Date 24/04/19 28/04/20 29/04/21 27/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,264 614.2 721.7 736 704.3 431.4
EBITDA 1 273.4 -396.6 -441.7 -112.7 -58.4 -132.7
EBIT 1 177.7 -497 -545.3 -237 -182.1 -281.5
Operating Margin 14.05% -80.92% -75.55% -32.2% -25.86% -65.25%
Earnings before Tax (EBT) 1 -333.7 -891.3 -588.2 33.68 -372.8 -511.1
Net income 1 -340.8 -884.8 -609.4 30.81 -370.6 -513.9
Net margin -26.95% -144.05% -84.44% 4.19% -52.61% -119.12%
EPS 2 -0.3700 -0.9600 -0.6600 0.0300 -0.4200 -0.5800
Free Cash Flow 1 -423.4 -446.5 -111.9 -169.4 -177.6 93.41
FCF margin -33.48% -72.69% -15.5% -23.01% -25.22% 21.65%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 24/04/19 28/04/20 29/04/21 27/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 207 1,210 1,496 1,173 1,540 1,665
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.7574 x -3.05 x -3.387 x -10.4 x -26.36 x -12.55 x
Free Cash Flow 1 -423 -446 -112 -169 -178 93.4
ROE (net income / shareholders' equity) -9.37% -31.5% -31.2% 1.71% -25.3% -49.6%
ROA (Net income/ Total Assets) 2.03% -5.98% -7.79% -3.74% -3.03% -5.11%
Assets 1 -16,814 14,790 7,819 -824.5 12,236 10,060
Book Value Per Share 2 3.660 2.190 1.850 1.790 1.440 0.9100
Cash Flow per Share 2 1.690 0.8100 0.5100 0.1600 0.1200 0.4100
Capex 1 366 570 244 199 190 81.8
Capex / Sales 28.91% 92.83% 33.76% 27.04% 26.95% 18.95%
Announcement Date 24/04/19 28/04/20 29/04/21 27/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
HYBIO PHARMACEUTICAL CO., LTD. Stock Hybio Pharmaceutical Co., Ltd.
-12.30% 1.52B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+18.71% 44.35B
SANDOZ GROUP AG Stock Sandoz Group AG
+19.44% 15.08B
CIPLA LIMITED Stock Cipla Limited
+19.49% 14.37B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+57.58% 13.06B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.70% 6.75B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+13.66% 5.64B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT. Stock Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
+4.00% 4.66B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300199 Stock
  4. Financials Hybio Pharmaceutical Co., Ltd.